Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/Pathologymedical mutual - ohio iron testing Coverage Update…
    Ask Trek AI about this page
    Modifiedmedical mutual - ohioPolicy AHS - G2011

    Diagnostic Testing of Iron Homeostasis & Metabolism

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - G2011 alerts

    Get alerted when Policy AHS - G2011 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage limits for laboratory testing of iron status (serum ferritin, transferrin saturation, hepcidin, GlycA) for Medical Mutual - Ohio members; applies to providers ordering iron-related laboratory tests.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDiagnostic Testing of Iron Homeostasis & Metabolism
    Policy CodePolicy AHS - G2011
    Change TypeRevised coverage criteria and frequency limitsadded new indications
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionOrder and document serum ferritin and TSAT only for listed indications and adhere to specified frequency limits (e.g., ≤1/month; 3-week interval for iron overload; quarterly or monthly for CKD).
    SourceLink
    POLICY UPDATE CHANGES

    CC1: added '(no more than one test per month unless otherwise specified)'.

    CC1b: clarified and added a frequency: 'Once every three weeks for individuals with an iron overload disorder.'

    CC1.h: edited to include CKD-dependent frequencies: one test every three months if not on dialysis; one test every month if receiving dialysis.

    New CC1.j: added coverage for individuals with restless legs syndrome or periodic limb movement disorder.

    New CC2.d: added coverage for individuals with restless legs syndrome or periodic limb movement disorder.

    Note 1 updated to align symptoms of hemochromatosis with Cleveland Clinic and expanded to include arrhythmias, erectile dysfunction, knuckle pain, and more specific abdominal pain location.

    CC1a edited for clarity.

    1/monthmax routine ferritin tests / month
    every 3 weeksferritin — iron overload
    1 per 3 monthsferritin — CKD (no dialysis)
    1/monthferritin — CKD (on dialysis)
    NOT COVEREDhepcidin testing
    12/03/2025last review

    Coverage Criteria for Iron-related Laboratory Testing

    inv-01: Serum ferritin — Covered indications

    Measurement of serum ferritin levels (no more than one test per month unless otherwise specified) MEETS COVERAGE CRITERIA when any of the following are present:

    Serum ferritin covered indications: a) Individual has anemia.

    No more than one test per month unless otherwise specified

    Serum ferritin covered indications: b) Individual has an iron overload disorder (testing allowed once every three weeks).>=21 days between tests

    Exception to general monthly cap for iron overload

    Serum ferritin covered indications: c) Individual has symptoms suggestive of hemochromatosis (see policy Note 1).
    Serum ferritin covered indications: d) Individual is a first-degree relative of a person with confirmed hereditary hemochromatosis.
    Serum ferritin covered indications: e) Evaluation of liver disease.
    Serum ferritin covered indications: f) Evaluation for hemophagocytic lymphohistiocytosis (HLH) or Still Disease.
    Serum ferritin covered indications: g) Males with secondary hypogonadism.
    Serum ferritin covered indications: h) Individuals with chronic kidney disease (CKD): i) One test every three months if not receiving dialysis; ii) One test every month if receiving dialysis.quarterly or monthly depending on dialysis status

    Frequency specified per KDIGO-aligned revision

    Serum ferritin covered indications: i) Individuals on iron therapy (monitoring).
    Serum ferritin covered indications: j) Individuals with restless legs syndrome (RLS) or periodic limb movement disorder (newly added indication).

    Newly added to covered indications

    inv-02: Transferrin saturation — Covered indications

    Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA when any of the following are present:

    Transferrin saturation covered indications: a) Evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1).
    Transferrin saturation covered indications: b) Evaluation of iron overload in first-degree relatives of individuals with confirmed hereditary hemochromatosis.
    Transferrin saturation covered indications: c) Evaluation of iron deficiency anemia (as part of iron studies: serum iron, TIBC, TSAT, ferritin).

    Use TSAT <20% as supportive of iron deficiency per guideline contexts

    Transferrin saturation covered indications: d) Individuals with restless legs syndrome or periodic limb movement disorder.

    AASM recommends TSAT and ferritin testing in clinically significant RLS

    inv-05: Revised coverage criteria and frequency rules

    ref':'b0_4
    title':'inv-05: Revised coverage criteria and frequency rules'},{

    Measurement of serum ferritin or transferrin (including transferrin saturation) for indications not explicitly listed in the policy does not meet coverage criteria and may be denied. The policy states that ferritin measurement meets coverage criteria when performed no more than one test per month unless otherwise specified, with specified exceptions (for example, iron overload and CKD frequencies) and explicit covered indications such as anemia, hemochromatosis evaluation, first‑degree relatives of confirmed hereditary hemochromatosis, liver disease evaluation, HLH/Still Disease, secondary hypogonadism in males, individuals on iron therapy, and restless legs syndrome/perioric limb movement disorder.

    Published guidance and the policy record that no established guidelines support using ferritin as a first‑line test in asymptomatic individuals. The policy therefore does not endorse routine ferritin screening of asymptomatic people and requires clinical indication aligned with the listed covered situations for coverage.

    The United States Preventive Services Task Force (USPSTF) has concluded that evidence is insufficient (Grade I) to recommend routine screening for iron deficiency anemia in asymptomatic pregnant individuals and in children aged 6–24 months. The policy references this determination when advising that routine asymptomatic screening in these populations is not supported by sufficient evidence.

    This revision cycle focused on adding explicit frequency limits and new covered indications rather than introducing new test exclusions. The Revision History documents the operational frequency caps (e.g., no more than one test per month unless otherwise specified, and specific exceptions such as once every three weeks for iron overload), plus the addition of restless legs syndrome as a covered indication.

    Serum hepcidin testing, including immunoassays, is explicitly stated in the policy as DOES NOT MEET COVERAGE CRITERIA. The policy cites lack of sufficient published scientific literature supporting clinical utility as the rationale for noncoverage.

    Measurement of ferritin as a routine first‑line screening test in asymptomatic individuals is not supported by identified published recommendations. The policy therefore limits coverage to defined clinical indications and frequency rules rather than permitting indiscriminate screening.

    USPSTF findings that current evidence is insufficient to recommend routine screening for iron deficiency anemia in asymptomatic pregnant individuals and children aged 6–24 months are cited by the policy. These determinations inform the policy stance that routine asymptomatic screening in pregnancy and young children is not supported by sufficient evidence and coverage is determined by documented clinical indication.

    Ordering tests more frequently than the policy allows (for example, exceeding one ferritin test per month where no exception applies) may be considered not medically necessary and is subject to denial. The Revision History and frequency rules emphasize adherence to the specified intervals (monthly cap, once every three weeks for iron overload, quarterly or monthly for CKD depending on dialysis status).

    Covered Indications and Clinical Uses

    Testing Frequency Limits and Monitoring Intervals

    serum ferritin — general frequency limit
    LimitNo more than one serum ferritin test per month unless otherwise specified.
    Applies toAll covered serum ferritin indications unless a different frequency is explicitly stated.
    Policy referenceIII. Indications and/or Limitations of Coverage — measurement of serum ferritin levels (no more than one test per month unless otherwise specified).
    serum ferritin for iron overload disorder
    FrequencyOnce every three weeks for individuals with an iron overload disorder.
    ContextSpecified exception to the general monthly cap for monitoring iron overload/hemochromatosis.

    Procedure and Diagnostic Codes

    Referenced procedure codesCPT
    82728Ferritin
    83540Iron
    83550Iron binding capacity
    84466Transferrin
    84999Unlisted chemistry procedure
    0024UGlycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (proprietary test: GlycA Lab/Manufacturer: Laboratory Corporation of America)
    0251UHepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma (proprietary test: Intrinsic Hepcidin IDx™)
    Ferritin/TSAT thresholds in inflammatory conditions
    Inflammatory conditions thresholdFerritin <100 μg/L or TSAT <20% indicates iron deficiency in inflammatory conditions; if ferritin is 100–300 μg/L then TSAT <20% is required to confirm deficiency.
    SourceDignass et al. recommendations and ICCAMS guidance referenced in policy analytical validity and guideline sections.
    Clinical useApply combined ferritin/TSAT criteria when inflammation may elevate ferritin despite iron deficiency.
    Standard iron deficiency threshold
    Standard thresholdSerum ferritin <30 μg/L is the standard threshold indicating iron deficiency.
    SourceAnalytical validity section: 'Low SF (<30 μg/L) is a sensitive and specific indicator for ID.'

    Provider Actions, Documentation, and Authorization Notes

    Prior Authorization

    No blanket prior authorization

    This policy contains no explicit prior authorization (PA) requirement for ferritin, transferrin/TSAT, or related iron studies; coverage is governed by the indications and frequency limits in the policy rather than a blanket PA rule.

    Prior Authorization

    IV iron authorization requires oral-trial / absorption documentation

    IV iron is recommended when oral iron is not tolerated, ferritin does not improve after an oral iron trial, or when absorption is likely impaired; documentation of the prior oral trial or of conditions limiting absorption may be required to authorize IV iron.

    Ordering Requirements and Recommended Test Panels

    Note

    Verify benefits; no provider-type restriction listed

    Coverage is dependent on the individual's benefit coverage at time of request; the policy does not impose a specific provider-type ordering restriction in this section.

    Note

    Order tests per specialty society guidance

    Order ferritin, serum iron, and TSAT in clinical contexts following specialty society guidance (AGA, ACG, ASCO/ASH, AAFP, WHO); for example, evaluate for hemochromatosis when abnormal liver chemistries are present.

    • Follow AGA/ACG recommendations for contexts such as anemia and abnormal liver chemistries.
    Note

    Order set for anemia evaluation (CBC + iron studies)

    When evaluating anemia, include a core order set of CBC, serum ferritin, serum iron, TIBC, and calculate TSAT; in inflammatory states consider reticulocyte hemoglobin content or hepcidin if available.

    Tests and Uses Not Covered

    The policy lists tests that are not covered: serum hepcidin testing (including immunoassays) and GlycA testing to measure or monitor transferrin or other glycosylated proteins do not meet coverage criteria. The GlycA analytic limitations (inability to accurately quantify individual protein concentrations) are cited as part of the rationale for noncoverage.

    GlycA is not an appropriate substitute for specific protein measurements such as transferrin because the GlycA NMR signal represents a composite of glycoprotein signals and cannot accurately determine individual protein concentrations. For that reason the policy states GlycA testing does not meet coverage criteria for measuring transferrin or other glycosylated proteins.

    The policy considers routine screening for iron deficiency anemia in asymptomatic pregnant people and children ages 6–24 months to have insufficient evidence for benefit, consistent with USPSTF Grade I findings; such routine screening is therefore not supported as a covered service in this policy.

    Within the updated policy window no additional specific tests were added to an explicit exclusion list; instead, the revisions primarily modify testing frequencies and add clinical indications (for example, restless legs syndrome) while restating that hepcidin and GlycA are not covered.

    Definitions and Biomarker Descriptions

    Definition — serum ferritin (SF)
    Serum ferritin (SF)Intracellular iron storage protein composed of FTL and FTH subunits; serum ferritin largely reflects iron stores but is also an acute phase reactant and can be elevated in inflammation, liver disease, malignancy, and other non‑overload states.
    Clinical noteSerum ferritin in healthy adults generally reflects overall iron storage and correlates with bone marrow/liver iron measures.
    MeasurementDetected in serum due to macrophage secretion or release during cell death; mostly composed of L subunits and partly glycosylated.
    Definition — hepcidin
    DefinitionHepcidin is a small peptide hormone that binds ferroportin causing its degradation and thereby regulates serum iron concentrations and systemic iron homeostasis.
    Function

    Background and Clinical Context

    Iron homeostasis involves intestinal absorption, transport by transferrin, cellular uptake via transferrin receptors, and storage in ferritin. Hepcidin is the central regulatory peptide that binds ferroportin and decreases iron export from cells; serum ferritin largely reflects body iron stores but is also an acute‑phase reactant and can be elevated in inflammation, liver disease, or malignancy, which may confound interpretation. Transferrin saturation (TSAT) is calculated from serum iron and total iron‑binding capacity and complements ferritin when assessing iron availability and distinguishing deficiency from inflammatory elevation of ferritin.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDiagnostic Testing of Iron Homeostasis & Metabolism
    Policy CodePolicy AHS - G2011
    Change TypeRevised coverage criteria and frequency limitsadded new indications
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionOrder and document serum ferritin and TSAT only for listed indications and adhere to specified frequency limits (e.g., ≤1/month; 3-week interval for iron overload; quarterly or monthly for CKD).
    SourceLink
    On This Page
    Coverage Criteria for Iron-related Laboratory TestingCovered Indications and Clinical UsesTesting Frequency Limits and Monitoring IntervalsProcedure and Diagnostic CodesProvider Actions, Documentation, and Authorization NotesOrdering Requirements and Recommended Test PanelsTests and Uses Not CoveredDefinitions and Biomarker DescriptionsBackground and Clinical Context
    Policy referenceIII. Indications and/or Limitations of Coverage — item b) and Revision History noting CC1b frequency addition.
    serum ferritin for CKD (not on dialysis)
    FrequencyOne test every three months if the individual is not receiving dialysis.
    ContextCKD monitoring frequency for non-dialysis patients per revised CC1.h.i and KDIGO recommendations for periodic testing.
    Policy referenceIII. Indications and/or Limitations of Coverage — CC1.h.i and Revision History describing CKD frequencies.
    serum ferritin for CKD (on dialysis)
    FrequencyOne test every month if the individual is receiving dialysis.
    ContextCKD monitoring frequency for patients on hemodialysis (monthly testing).
    Policy referenceIII. Indications and/or Limitations of Coverage — CC1.h.ii and Revision History describing CKD dialysis frequency.
    serum hepcidin — suggested interval (thalassemia)
    FrequencyEvery 6 months (suggested individual evaluation/follow‑up interval for thalassemia patients).
    ContextAuthors recommend individual evaluation and follow-up; periodic six‑monthly hepcidin measurement may be valuable in thalassemia.
    EvidenceIsmail et al. (2019) — individual evaluation and follow up e.g. every six months could be valuable.
    Hemoglobin, ferritin, TSAT — quarterly
    FrequencyEvery 3 months for routine monitoring (e.g., CKD patients not on dialysis; post‑treatment monitoring).
    TestsHemoglobin, ferritin, transferrin saturation (TSAT).
    ContextKDIGO and guideline-based recommendations support testing these parameters at least quarterly in relevant populations.
    Hemoglobin, ferritin, TSAT — monthly
    FrequencyMonthly monitoring (e.g., during hemodialysis or when initiating/increasing ESA or iron therapy).
    TestsHemoglobin, ferritin, transferrin saturation (TSAT).
    ContextKDIGO recommends monthly testing for patients receiving hemodialysis or during active iron/ESA treatment changes.
    Ferritin — recheck interval after normalization or supplementation
    RecommendationRecheck ferritin 3–6 months after normalization or after initiation of supplementation.
    ContextMonitoring response to oral iron and to confirm replenishment of iron stores after anemia correction.
    Guidance sourceGovernment of British Columbia guideline monitoring steps (recheck ferritin 3–6 months).
    Serum ferritin — ASH recommended monitoring frequency
    FrequencyEvery 3–6 weeks (recommended by ASH for calculating ferritin running averages).
    PurposeFrequent checks allow running averages to correct for transient fluctuations due to inflammation or liver injury.
    Guideline sourceAmerican Society of Hematology — recommend checking ferritin every 3–6 weeks for running averages.
    CC1 group of tests — monthly cap
    LimitNo more than one test per month for CC1 group tests unless otherwise specified.
    ScopeApplies to the CC1 group of tests referenced in the policy (frequency cap operationalized for routine ordering).
    Policy referenceRevision History and III. Indications — CC1 general frequency cap added in update.
    individuals with an iron overload disorder — testing frequency
    FrequencyOnce every three weeks for individuals with an iron overload disorder.
    Applies toIndividuals monitored for hemochromatosis or other iron overload conditions where more frequent ferritin monitoring is indicated.
    Policy referenceIII. Indications item b) and Revision History noting CC1b frequency addition.
    individuals with CKD not receiving dialysis — testing frequency
    FrequencyOne test every three months for individuals with CKD not receiving dialysis.
    ContextConsistent with KDIGO guidance to test hemoglobin, ferritin, and TSAT at least every three months in non‑dialysis CKD when treated with iron/ESA.
    Policy referenceIII. Indications CC1.h.i and Revision History describing CKD frequencies.
    individuals with CKD receiving dialysis — testing frequency
    FrequencyOne test every month for individuals with CKD receiving dialysis.
    ContextMonthly testing aligns with KDIGO recommendation for hemodialysis patients to monitor hemoglobin, ferritin, and TSAT.
    Policy referenceIII. Indications CC1.h.ii and Revision History noting CKD dialysis frequency.
    Clinical noteIn non‑inflammatory settings this cutoff is widely used to define absolute iron deficiency.
    Selected ferritin thresholds and triggers
    Selected thresholdsExamples: ferritin >200 ng/mL (women) or >300 ng/mL (men) warrant additional testing; ferritin >1000 ng/mL may indicate need for therapeutic phlebotomy; very high values reported in HLH (eg, >3951 ng/mL).
    ContextThresholds derived from HEIRS study and HLH diagnostic literature cited in clinical utility section.
    PurposeUse these thresholds to prompt further evaluation for iron overload, HLH, or need for therapeutic phlebotomy.
    CKD iron therapy withholding thresholds
    Withholding thresholds (CKD)Withhold iron therapy if ferritin ≥700 ng/mL or TSAT ≥40%.
    Source2024 KDIGO Clinical Practice Guideline for Anemia in CKD — recommends withholding iron at these thresholds.
    Clinical implicationAvoid IV/oral iron administration when thresholds exceeded to reduce risk of iron overload/toxicity.
    Billing Rule

    Procedure codes listed (reference only)

    Procedure codes for ferritin and iron studies are provided for reference; the document does not impose prior authorization tied to these CPT/HCPCS codes.

    • Referenced CPT codes include 82728 (ferritin), 83540 (iron), 83550 (TIBC), 84466 (transferrin) and proprietary codes 0024U (GlycA) and 0251U (hepcidin).
    Prior Authorization

    Follow frequency and indication rules rather than expecting blanket PA

    There is no blanket prior authorization; instead follow the policy's operational requirements for covered indications and specified frequency limits when requesting coverage.

    Step Therapy

    Oral-first approach before IV iron

    Whenever possible, attempt an every‑other‑day oral iron regimen as first‑line therapy because it is often better tolerated and absorbed; IV iron is reserved for intolerance, lack of response after an oral trial, or impaired absorption.

    • Every-other-day oral iron may be better tolerated and has similar absorption compared to daily dosing.
    • Use IV iron if oral iron is not tolerated, ferritin does not improve after an oral trial, or absorption is likely impaired.
    Step Therapy

    Therapy sequencing: oral → assess → consider IV

    Treat iron deficiency with oral iron as first‑line therapy and monitor response per guideline recommendations; escalate to IV iron only per the oral‑first approach and documented clinical need.

    • Oral iron is first-line; monitor hemoglobin/ferritin response and reassess before proceeding to IV therapy.
    Documentation Required

    Benefit verification required

    Verify the member's current benefit coverage at the time of the request and apply the policy's coverage criteria and frequency limits to the individual's benefits.

    Documentation Required

    Laboratory and clinical documentation to support orders

    Document relevant laboratory and clinical data when ordering iron studies: include ferritin, TSAT (transferrin saturation), and inflammatory markers (e.g., CRP) where inflammation or CKD may affect ferritin interpretation; record prior treatments and response to oral or IV iron.

    • Document ferritin and TSAT whenever interpretation may be confounded by inflammation or CKD (consider CRP).
    • Record prior oral iron trial and documented response when IV iron is considered.
    Documentation Required

    Monitoring documentation: serial CBC and ferritin per guidance

    Monitor therapeutic response with serial CBC and ferritin measurements; recheck ferritin 3–6 months after normalization or after initiation of supplementation and follow CKD-specific monitoring cadence (every 3 months if not on dialysis; monthly if on dialysis).

    • Recheck ferritin 3–6 months after normalization or after starting supplementation.
    • For CKD patients: test hemoglobin, ferritin, and TSAT every 3 months if not on dialysis, monthly if on hemodialysis.
    Documentation Required

    Support orders with indication and frequency documentation

    Include documentation that supports the specific covered indication and adheres to the policy's frequency limits (e.g., iron overload, CKD dialysis status, restless legs syndrome) when ordering tests to avoid denials.

    • Specify the indication category (iron overload disorder, CKD with/without dialysis, RLS, anemia, etc.) in the order.
    • Ensure testing interval requested matches frequency limits in policy (monthly, quarterly, or every 3 weeks as specified).
    Denial Risk

    Risk of denial for tests outside listed indications

    Ordering ferritin, transferrin, or TSAT for indications not listed in the policy does not meet coverage criteria and may be denied; ensure the clinical indication aligns with the policy's covered situations before ordering.

    • Tests outside listed indications (including routine screening in asymptomatic individuals) are not covered per the policy.
    Denial Risk

    Hemochromatosis workup required to avoid missed diagnosis

    When evaluating abnormal liver chemistries for possible hereditary hemochromatosis, perform iron level, transferrin saturation, and serum ferritin as recommended; failure to perform these tests risks missing a diagnosis and may lead to clinical/coverage issues.

    • ACG recommends testing iron, TSAT, and serum ferritin in patients with abnormal liver chemistries in the absence of acute hepatitis.
    Note

    Government policies take precedence

    If state or federal government policy (LCD/NCD/Medicaid) conflicts with this policy, the applicable government policy takes precedence and will be used to make coverage determinations.

    Denial Risk

    Denial risk for frequency noncompliance

    Ordering tests more frequently than the policy permits (e.g., exceeding one ferritin test per month where not otherwise allowed, or more frequent than specified for iron overload or CKD) may trigger denial as not medically necessary.

    • General cap: no more than one serum ferritin test per month unless a subcriterion specifies a different frequency.
    • Exceptions: once every three weeks for iron overload; CKD: quarterly if not on dialysis, monthly if on dialysis.
    • Core tests: CBC, ferritin, serum iron, TIBC, TSAT.
    • Consider RET‑He or hepcidin in inflammatory states when available.
    Documentation Required

    Document clinical indication and frequency on orders

    The order must document the clinical indication that aligns with the coverage criteria and must adhere to specified frequency limits to be considered covered.

    • Include the covered indication on the laboratory order.
    • Confirm requested test timing meets policy frequency limits.
    Hepcidin production is sensitive to extracellular iron and is regulated via HFE and transferrin receptor signaling (BMP‑SMAD pathway).
    Clinical implicationHepcidin assays have diagnostic implications, but serum hepcidin testing is not covered due to limited published clinical utility evidence in this policy.
    Low serum ferritin — definition and caveats
    Low SF definitionSF <30 μg/L is a sensitive and specific indicator for iron deficiency in non‑inflammatory settings.
    Inflammation adjustmentIn inflammatory conditions, higher ferritin thresholds (eg, <100 μg/L with TSAT <20%) may be required to diagnose iron deficiency.
    SourceAnalytical validity and ICCAMS recommendations cited in policy.
    WHO ferritin cut-offs
    WHO cutoffs (healthy individuals)Ferritin <12 μg/L for infants/preschool healthy; <15 μg/L for many older groups to indicate deficiency.
    Inflammation adjustmentHigher cutoffs (eg, up to 30–70 μg/L) recommended in presence of infection/inflammation depending on age and context.
    SourceWHO guideline on use of ferritin concentrations to assess iron status (2020).
    Definition — Transferrin saturation (TSAT)
    DefinitionTransferrin saturation (TSAT) is calculated from serum iron and total iron binding capacity and indicates iron availability; TSAT <20% suggests iron deficiency and values >85% indicate risk for non‑transferrin‑bound iron.
    Clinical useUse TSAT together with ferritin when inflammation may affect ferritin; TSAT is widely available but can be confounded by chelators or recent iron therapy.
    SourceASH and ICCAMS guidance referenced in policy.
    Ferritin thresholds — overview
    Variable cutoffsRecommended ferritin cutoffs vary by population and inflammation status: examples include <12 µg/L for infants (healthy), <15 µg/L for adults (healthy), <30 µg/L in some settings with inflammation, and higher cutoffs (up to ~100 µg/L) for active inflammatory disease.
    ApplicationChoose cutoffs based on patient age, pregnancy status, and presence of inflammation per WHO/ICCAMS/ECCO guidance.
    SourceWHO, ICCAMS, ECCO guidelines cited in policy's guideline section.
    Definition — hemochromatosis / iron overload
    DefinitionHemochromatosis (iron overload) is a clinical syndrome of excess iron deposition; ferritin and TSAT are used to evaluate suspected cases and guide therapy.
    Clinical actionElevated ferritin and TSAT prompt additional testing; therapeutic phlebotomy indicated at high SF/TSAT thresholds per cited guidance.
    ReferenceCleveland Clinic guidance and HEIRS study cited in policy references and clinical utility.
    Definition — hepcidin (assay considerations)
    Hepcidin clinical roleHepcidin is a regulatory peptide with diagnostic implications in iron disorders; assays (ELISA, HPLC/LC‑MS/MS) are discussed in referenced studies.
    Assay methodsAnalytic methods for hepcidin include ELISA and HPLC/LC‑MS/MS; validated laboratory methods are important for reliable results.
    Policy stanceDespite analytic methods, serum hepcidin testing is listed as not meeting coverage criteria in this policy due to limited clinical utility evidence.